Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Brain & mental health · 2026

Zanvastro (zilganersen)

The FDA approved Zanvastro (zilganersen) on September 3, 2026 to treat Alexander disease in pediatric and adult patients.
Brand name
Zanvastro
Generic name
zilganersen
FDA approval date
September 3, 2026
Approved use (FDA wording)
To treat Alexander disease in pediatric and adult patients
Category on this site
Brain & mental health

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.